SGLT2 Inhibitors in Kidney Diseases—A Narrative Review

Abstract

Some of the most common conditions affecting people are kidney diseases. Among them, we distinguish chronic kidney disease and acute kidney injury. Both entities pose serious health risks, so new drugs are still being sought to treat and prevent them. In recent years, such a role has begun to be assigned to sodium-glucose cotransporter-2 (SGLT2) inhibitors. They increase the amount of glucose excreted in the urine. For this reason, they are currently used as a first-line drug in type 2 diabetes mellitus. Due to their demonstrated cardioprotective effect, they are also used in heart failure treatment. As for the renal effects of SGLT2 inhibitors, they reduce intraglomerular pressure and decrease albuminuria. This results in a slower decline in glomelular filtration rate (GFR) in patients with kidney disease. In addition, these drugs have anti-inflammatory and antifibrotic effects. In the following article, we review the evidence for the effectiveness of this group of drugs in kidney disease and their nephroprotective effect. Further research is still needed, but meta-analyses indicate SGLT2 inhibitors' efficacy in kidney disease, especially the one caused by diabetes. Development of new drugs and clinical trials on specific patient subgroups will further refine their nephroprotective effects.

Exploring the Significance of Gut Microbiota in Diabetes Pathogenesis and Management—A Narrative Review

“…This has led to the pursuit of new therapeutic options and a greater understating of the pathophysiology of DM. Recent advancements in treatment have introduced new pharmacotherapies, targeting key pathways such as GLP-1Ras, DPP-4, and SGLT-2 inhibitors, which influence the progression of T2DM and its complications [6,7]. Approximately 90% to 95% of DM cases are diagnosed as DMT2, which is related to multi-genetic and environmental factors [8].…”

“…This has led to the pursuit of new therapeutic options and a greater understating of the pathophysiology of DM. Recent advancements in treatment have introduced new pharmacotherapies, targeting Nutrients 2024, 16,1938 2 of 18 key pathways such as GLP-1Ras, DPP-4, and SGLT-2 inhibitors, which influence the progression of T2DM and its complications [6,7].…”